Baricitinib set to join the Covid-19 therapeutic arsenal?
作者信息
Gudu Tania, Stober Carmel, Cope Andrew P, Cheriyan Joseph, Galloway James, Wilkinson Ian B, Kostapanos Michalis, Jayne David, Hall Frances
机构信息
Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Centre for Rheumatic Disease, King's College London, London, UK.
出版信息
Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
Abstract
摘要
相似文献
1
Baricitinib set to join the Covid-19 therapeutic arsenal?巴瑞替尼会加入新冠治疗药物库吗？
Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
2
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.巴利昔替尼的作用机制支持人工智能预测在 COVID-19 患者中的检测。
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
3
Baricitinib: From Rheumatoid Arthritis to COVID-19.巴瑞替尼：从类风湿关节炎到 COVID-19。
J Clin Pharmacol. 2021 Oct;61(10):1274-1285. doi: 10.1002/jcph.1874. Epub 2021 Jun 12.
4
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.COVID-19 治疗的免疫调节剂：可能的作用机制和免疫病理学特征。
Mol Cell Biochem. 2022 Mar;477(3):711-726. doi: 10.1007/s11010-021-04325-9. Epub 2022 Jan 11.
5
JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.在 SARS-CoV-2 感染的早期阶段抑制 JAK 会通过抑制内源性抗病毒活性而使小鼠的肾脏损伤恶化。
Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F931-F941. doi: 10.1152/ajprenal.00011.2024. Epub 2024 Apr 18.
6
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.JAK 抑制可降低 SARS-CoV-2 的肝脏感染性，并调节炎症反应，从而降低发病率和死亡率。
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abe4724. Print 2021 Jan.
7
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.巴瑞替尼：关于COVID-19的药理学、安全性及新出现临床经验的综述
Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27.
8
The effect of drugs used in rheumatology for treating SARS-CoV2 infection.风湿病药物治疗 SARS-CoV2 感染的效果。
Expert Opin Biol Ther. 2021 Feb;21(2):219-228. doi: 10.1080/14712598.2020.1817372. Epub 2020 Sep 18.
9
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.巴瑞替尼，一种具有潜在作用的药物，可以阻止 SARS-COV-2 进入靶细胞，并控制由 COVID-19 引起的细胞因子风暴。
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
10
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
引用本文的文献
1
A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019.托法替布的叙述性综述：其特性、功能及对治疗2019冠状病毒病的效用
Int J Crit Illn Inj Sci. 2023 Oct-Dec;13(4):192-198. doi: 10.4103/ijciis.ijciis_27_23. Epub 2023 Dec 26.
2
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.巴瑞替尼或瑞维鲁单抗治疗成人重症 COVID-19 患者的疗效和安全性（TACTIC-R）：一项随机、平行臂、开放标签、四期临床试验。
Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14.
3
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.JAK/STAT抑制剂在儿科的新应用：芦可替尼的当前应用情况
Pharmaceuticals (Basel). 2022 Mar 19;15(3):374. doi: 10.3390/ph15030374.
4
What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19.危重症与创伤科学领域有哪些新进展？一项关于Janus激酶抑制剂对COVID-19入院患者28天死亡率影响的循证分析。
Int J Crit Illn Inj Sci. 2021 Jul-Sep;11(3):109-111. doi: 10.4103/ijciis.ijciis_80_21. Epub 2021 Sep 25.
5
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
本文引用的文献
1
Genetic mechanisms of critical illness in COVID-19.新型冠状病毒肺炎危重症的遗传机制。
Nature. 2021 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.JAK 抑制剂相关的静脉血栓栓塞风险：一项荟萃分析。
Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25.
4
Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies.新型冠状病毒肺炎发病机制中的免疫失同步及其潜在免疫治疗策略。
J Exp Med. 2020 Oct 5;217(10). doi: 10.1084/jem.20200674.
5
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
6
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.用于 ICU 前新冠患者的免疫调节药物再利用 - 新冠 ICU 前住院患者的多臂治疗研究 - 再利用药物（TACTIC-R）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 8;21(1):626. doi: 10.1186/s13063-020-04535-4.
7
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.巴瑞替尼：关于COVID-19的药理学、安全性及新出现临床经验的综述
Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27.
8
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.巴利昔替尼的作用机制支持人工智能预测在 COVID-19 患者中的检测。
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
9
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.Janus 激酶抑制剂在炎症性肠病或其他免疫介导性疾病患者中的安全性：系统评价和荟萃分析。
Gastroenterology. 2020 May;158(6):1554-1573.e12. doi: 10.1053/j.gastro.2020.01.001. Epub 2020 Jan 9.
Zotero 插件